Last kr67.50 DKK
Change Today +2.00 / 3.05%
Volume 39.0K
As of 11:02 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (ZEAL) Snapshot

Open
kr66.00
Previous Close
kr65.50
Day High
kr67.50
Day Low
kr65.50
52 Week High
09/11/13 - kr79.50
52 Week Low
10/1/13 - kr55.50
Market Cap
1.6B
Average Volume 10 Days
21.6K
EPS TTM
kr-8.10
Shares Outstanding
23.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZEALAND PHARMA A/S (ZEAL)

Related News

No related news articles were found.

zealand pharma a/s (ZEAL) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (ZEAL) Details

Zealand Pharma A/S, a biotechnology company, discovers and develops peptide drugs in Denmark. Its lead drug includes Lyxumia (lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company’s product pipeline also comprise Lantus and Lyxumia, which are in Phase III clinical trials for the treatment of type 2 diabetes; and ZP2929, a once-daily dual acting glucagon/GLP-1 peptide agonist that is in Phase I clinical trial for the treatment of diabetes and/or obesity. In addition, it develops danegaptide, a dipeptide gap junction modifier in Phase II clinical study with cardioprotective properties; ZP1480, an MSH melanocortin peptide agonist in Phase IIb clinical trial for the prevention of acute kidney injury following surgery; Elsiglutide, a GLP-2 peptide receptor agonist in Phase II clinical trial for the prevention of chemotherapy induced diarrhea; and ZP1848, a GLP-2 peptide agonist that has completed Phase Ib trial for the treatment of inflammatory bowel disease. Further, the company has peptide drug programs in various stages of pre-clinical development, primarily in the fields of cardio-metabolic diseases, diabetes, and obesity. Zealand Pharma A/S has collaboration agreements with Sanofi S.A.; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; Abbvie Inc.; and Eli Lilly. The company was founded in 1998 and is based in Copenhagen, Denmark.

90 Employees
Last Reported Date: 04/29/14
Founded in 1998

zealand pharma a/s (ZEAL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zealand pharma a/s (ZEAL) Key Developments

Zealand Pharma A/S Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 09:30 AM

Zealand Pharma A/S Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 09:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: David Horn Solomon, Chief Executive Officer and President.

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S held its AGM on April 29, 2014. At the meeting, Bente Anderskouv, shareholder representative and Rémi Droller, shareholder representative were elected as members of the Nomination Committee. Jutta of Rosenborg did not stand for re-election.

Zealand Pharma A/S Appoints Deloitte Statsautoriseret Revisionspartnerselskab as its New Auditor

Zealand Pharma A/S at its AGM held on April 29, 2014 appointed Deloitte Statsautoriseret Revisionspartnerselskab as its new auditor.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEAL:DC kr67.50 DKK +2.00

ZEAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEAL.
View Industry Companies
 

Industry Analysis

ZEAL

Industry Average

Valuation ZEAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.4x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.